Compare Stocks

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQXP Aquinox Pharmaceuticals	$35.39 +4.8%	$3.94	$2.00 ▼ $3.84	$833.08M	-7.37	239,362 shs	78,640 shs
ETNB 89bio	$9.30 +5.0%	$10.88	$6.57 ▼ $22.93	$885.55M	1.15	1.18 million shs	8,090 shs
SAVA Cassava Sciences	$22.05 0.0%	$21.37	$12.32 ▼ $32.10	$953.66M	-0.38	768,215 shs	46,349 shs
SPRY ARS Pharmaceuticals	$9.65 +2.0%	$8.99	$2.55 ▼ $11.27	$934.99M	0.88	602,254 shs	10,150 shs

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQXP Aquinox Pharmaceuticals	+4.80%	+18.48%	-20.63%	+15.05%	+3,789.44%
ETNB 89bio	+1.26%	+7.39%	-16.26%	-10.82%	-46.14%
SAVA Cassava Sciences	-0.36%	+1.52%	+11.92%	-7.27%	+38.43%
SPRY ARS Pharmaceuticals	+1.39%	+16.93%	+1.94%	+48.98%	+43.33%

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQXP Aquinox Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	2.4866 of 5 stars	4.4	2.0	0.0	0.0	2.4	1.7	0.0
SAVA Cassava Sciences	3.2229 of 5 stars	3.5	0.0	0.0	4.7	2.3	0.0	0.6
SPRY ARS Pharmaceuticals	3.0665 of 5 stars	3.5	1.0	0.0	0.0	3.2	5.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQXP Aquinox Pharmaceuticals	N/A	N/A	N/A	N/A
ETNB 89bio	2.71	Moderate Buy	$29.00	211.83% Upside
SAVA Cassava Sciences	3.00	Buy	$124.00	462.36% Upside
SPRY ARS Pharmaceuticals	3.00	Buy	$18.50	91.71% Upside

Current Analyst Ratings

Latest AQXP, SPRY, ETNB, and SAVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	ETNB 89bio	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
4/5/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00
3/27/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/13/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/11/2024	SPRY ARS Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$19.00
3/6/2024	ETNB 89bio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$29.00 ➝ $37.00
3/5/2024	ETNB 89bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
3/5/2024	SAVA Cassava Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$124.00
3/5/2024	SPRY ARS Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/5/2024	SPRY ARS Pharmaceuticals	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$6.00 ➝ $18.00
3/4/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00

(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQXP Aquinox Pharmaceuticals	$25M	33.32	N/A	N/A	$3.09 per share	11.45
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.26 per share	N/A
SPRY ARS Pharmaceuticals	$30K	31,166.28	N/A	N/A	$2.40 per share	4.02

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQXP Aquinox Pharmaceuticals	-$31.58M	N/A	0.00	∞	N/A	N/A	-30.13%	-28.08%	N/A
ETNB 89bio	-$142.19M	-$2.01	N/A	N/A	N/A	N/A	-31.01%	-27.84%	N/A
SAVA Cassava Sciences	-$97.22M	-$2.32	N/A	13.20	N/A	N/A	-57.53%	-52.58%	5/6/2024 (Estimated)
SPRY ARS Pharmaceuticals	-$54.37M	-$0.57	N/A	N/A	N/A	N/A	-22.24%	-21.50%	5/20/2024 (Estimated)

Latest AQXP, SPRY, ETNB, and SAVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/21/2024	Q4 2023	SPRY ARS Pharmaceuticals	-$0.14	-$0.07	+$0.07	-$0.07	N/A	N/A
2/29/2024	Q4 2023	ETNB 89bio	-$0.49	-$0.50	-$0.01	-$0.50	N/A	N/A
2/28/2024	Q4 2023	SAVA Cassava Sciences	-$0.40	-$0.50	-$0.10	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQXP Aquinox Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQXP Aquinox Pharmaceuticals	N/A	63.17	63.17
ETNB 89bio	0.05	20.04	20.04
SAVA Cassava Sciences	N/A	9.13	9.13
SPRY ARS Pharmaceuticals	N/A	96.92	96.92

Ownership

Institutional Ownership

Company	Institutional Ownership
AQXP Aquinox Pharmaceuticals	71.69%
ETNB 89bio	N/A
SAVA Cassava Sciences	38.05%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
AQXP Aquinox Pharmaceuticals	4.00%
ETNB 89bio	4.40%
SAVA Cassava Sciences	9.00%
SPRY ARS Pharmaceuticals	35.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AQXP Aquinox Pharmaceuticals	8	23.54 million	N/A	Not Optionable
ETNB 89bio	70	95.22 million	91.04 million	Optionable
SAVA Cassava Sciences	29	43.25 million	39.35 million	Optionable
SPRY ARS Pharmaceuticals	24	96.89 million	62.40 million	Optionable

AQXP, SPRY, ETNB, and SAVA Headlines

Source	Headline
	ARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7.5% marketbeat.com - May 1 at 4:49 PM
	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 30 at 9:10 PM
	ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand finance.yahoo.com - April 30 at 10:18 AM
	ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand globenewswire.com - April 30 at 9:01 AM
	Insider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679K msn.com - April 26 at 3:05 PM
	ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up to $8.21 americanbankingnews.com - April 25 at 5:51 AM
	Ars Pharmaceuticals CEO sells over $928k in company stock investing.com - April 19 at 1:04 AM
	ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 3.4% Following Insider Selling marketbeat.com - April 18 at 12:17 PM
	ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares insidertrades.com - April 18 at 6:16 AM
	IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 15 at 3:00 AM
	ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Short Interest Update marketbeat.com - April 13 at 7:26 PM
	Ars Pharmaceuticals CEO sells shares worth over $927k investing.com - April 12 at 2:42 AM
	Ars pharmaceuticals exec sells shares worth over $927k investing.com - April 12 at 2:42 AM
	ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 100,000 Shares insidertrades.com - April 11 at 6:37 AM
	SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 11 at 3:30 AM
	ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.8% marketbeat.com - April 9 at 11:46 AM
	ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 8 at 7:30 PM
	ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.1% marketbeat.com - April 5 at 12:51 PM
	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 5 at 7:00 AM
	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm accesswire.com - April 4 at 3:00 AM
	ARS Pharma Submits Addl. Data In Response To FDA's CRL For Neffy markets.businessinsider.com - April 3 at 11:54 AM
	Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation finance.yahoo.com - April 3 at 11:54 AM
	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) globenewswire.com - April 3 at 9:01 AM
	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know zacks.com - April 1 at 1:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aquinox Pharmaceuticals

NASDAQ:AQXP

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

89bio

NASDAQ:ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Cassava Sciences

NASDAQ:SAVA

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

ARS Pharmaceuticals

NASDAQ:SPRY

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial